Radiation Oncologist @Unispital_USZ | former research scholar @MSKCancerCenter | interested in 🫁, reirradiation & oligometastatic disease
Zurich, Switzerland
Joined March 2014
- Tweets490
- Following720
- Followers474
- Likes1.5K
Pinned Tweet
Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths.
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO
ALT 📄 @JCO_ASCO https://ascopubs.org/doi/full/10.1200/JCO-25-01958
Jonas Willmann, MD retweeted
Randomized data shows PFS and OS benefit for SBRT/SABR for panc cancer. Congrats to Australasian GI Trials Group for completing this study. #radonc @Aiims1742 @TedHong9 @Dan_ChangMD @PrajnanDasMD @MikeChuongMD
sciencedirect.com/science/ar…
Jonas Willmann, MD retweeted
Delighted to share this new paper in the European Journal of Cancer: radical local treatment for NSCLC patients with oligoprogression after chemoradiation and durvalumab. 🫁
doi.org/10.1016/j.ejca.2026.…
Jonas Willmann, MD retweeted
🔥 Outstanding piece of work published today in Nature Medicine!
Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏
The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy?
This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients.
Congratulations to everyone involved! 👏
🔗 nature.com/articles/s41591-0…
Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors
#ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch
Jonas Willmann, MD retweeted
Proud to report at #ESMO2026 the results of PE-PE trial. Oligometastatic #RCC pts have a significant benefit when pembro was added to MDT irrespectively of the type of MDT used and up to 5y from previous surgery.
Thanks to the 🇮🇹 team and special thanks to @DrChoueiri!
@OncoAlert @urotoday @myESMO @KidneyCancer @Sebastiano_Buti @ciccarese_c @fmassari79 @mimma_rizzo @elena_verzoni @MatteoSantoniMD
Jonas Willmann, MD retweeted
#ESMO26 Does Tarlatamab provide long term benefit to responding patients?
✅The answer is Yes!
➡️Extended F-UP of the Dellphi-304 trial shows that after 22m of F-UP Landmark 2-year OS was 30% vs 15% and sustained disease control in 24% of patients at > 52 weeks
❓We need to investigate the characteristics of those patients to understand how we can improve the outcomes of the 70% of patients who do not make it to two years
@myESMO
#ESMOAmbassadors
Jonas Willmann, MD retweeted
#ESMO26 Dr. @fifimcdrmh presents the SARON trial. Phase II of consolidation radiotherapy vs systemic therapy in pts with driver negative oligometastatic NSCLC after 6-8w of control with systemic therapy. Improvement in PFS with radiation 13.9 vs 8.9m but no difference in OS.
Jonas Willmann, MD retweeted
Presenting the UK’s SARON study Dr @fifimcdrmh to a full hall at #ESMO26
In patients with de novo oligometastatic mutation driver negative #NSCLC , consolidation radiotherapy to the primary and metastases improved PFS but no OS
No significant difference in QOL or AEs
Huge thanks to all the patients and trialists involved
Jonas Willmann, MD retweeted
Now in Nature w simultaneous presentation #ESMO26 #NeoCOAST2 ! 1st platform neoadjuvant trial to associate tumor agnostic ctDNA dynamics w pCR & EFS! Privileged to be part of this effort led by Drs. Lara McGrath & Tina Cascone! Paper/slides below! 1/ #lcsm
nature.com/articles/s41586-0…
Jonas Willmann, MD retweeted
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM in conjunction with presentation @myESMO #ESMO26
the long-awaited #PracticeChanging results of:
⭐️#DeLLphi305 phase 3 trial of:
❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab.
Study showed:
‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit.
✅#mOS: 21.1 vs 12.7 months (HR 0.42)
✅12-month OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 months (HR 0.34)
⚠️ Grade ≥3 #AEs: 46.8% vs 40.6%
* In Tarlatamab arm:
#CRS: 49.6% (Grade ≥3: 0.4%)
#ICANS: 1.1% (Grade ≥3: 0%)
👇🏻
nejm.org/doi/full/10.1056/NE…
Jonas Willmann, MD retweeted
Yes, it works in pancreatic cancer.
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
Jonas Willmann, MD retweeted
DeLLphi-305 - tarlatamab added to durvalumab after initial chemo-immunotherapy for small lung cancer essentially doubles survival. Hope for all cancers here, if the right target & treatment modality can be refined. Unquestionably a new standard for this disease. #ESMO2026
Jonas Willmann, MD retweeted
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
Jonas Willmann, MD retweeted
Led by Drs @SafaviaA and @IMRTLee in @JAMAOnc: Can we safely reduce elective radiation dose in HPV+ oropharyngeal cancer?
Our study provides 5-yr evidence supporting elective nodal de-escalation to just 30 Gy, while maintaining excellent disease control.
jamanetwork.com/journals/jam…
Now in @JAMAOnc:
We report 5y outcomes post 30 Gy elective RT (total 70 Gy CCRT) for 276 pts w/ HPV-related OPC #hncsm at @MSKCancerCenter #radonc
LRC 97.0%
OS 90.8%
PFS 85.9%
DMFS 91.2%
@imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @EChrisDee
👉 shorturl.at/liqpP
Jonas Willmann, MD retweeted
Congrats to the SARON investigators! Important randomized data for a question we face all the time. 👏
Consolidation RT improved local control and PFS, but no OS benefit demonstrated: HR 0.99 (95% CI 0.63-1.55).
The RT details caught my eye. Of 62 pts who received RT, 51 had conventional treatment to the primary and only 11 had primary SABR. About 53% of the full cohort had N2/3 disease.
Side note: in the separate 13-pt ESTRO safety substudy, the most common schedules were 55 Gy/20 fx to the primary (10/13 pts) and 27 Gy/3 fx to thoracic mets (4/14 lesions). Those are substudy doses, not the dose distribution for the whole trial.
Curious how pts who actually received SABR to all sites did. That would be exploratory, but I'd like to see the dose/volume details and patterns of failure before generalizing these results to patients receiving total consolidation.
Looking forward to the full paper! #ESMO26 #radonc
cslide.ctimeetingtech.com/es…
Jonas Willmann, MD retweeted
How to plan and deliver lung cancer reirradiation: A consensus approach from the ESTRO reirradiation and lung focus groups and ReCOG - Radiotherapy and Oncology thegreenjournal.com/article/…
Jonas Willmann, MD retweeted
🚨🔔🔔Very happy to announce that we have randomised the first patient into @TOGAANZ and @TROGfightcancer phase III, PRIME-lung trial! First site open @PeterMacCC
➡️ this newly open 420 patient phase III trial investigates whether the addition of high dose radiation to the lung primary in patients with non-small cell lung cancer can be life-prolonging (primary endpoint OS)
➡️ Thank you all investigators and patients, this is just the beginning! #lungcancer #lcsm
Jonas Willmann, MD retweeted
OptiTROP-Lung05: 🫁
A strong phase 3 signal for ADC + immunotherapy in 1L PD-L1+ advanced NSCLC.
Sac-TMT + pembrolizumab vs pembrolizumab:
• PFS: NR vs 5.7 months; HR 0.35
• ORR: 70.2% vs 42.0%
thelancet.com/journals/lance…
@OncoAlert #lcsm #LungCancer
Jonas Willmann, MD retweeted
📍 Yesterday at the European Parliament, Prof @piet_ost represented ESTRO for the launch of the EAU #KidneyCancer White Paper.
Multidisciplinary care saves lives when interventions like #SABR are accessible without disparity.
Thanks to our host MEPs and EAU! 🙏
#radonc #Urology
Jonas Willmann, MD retweeted
Proud of our @nyulangone Dean (and prior @Perlmutter_CC Director) Alec Kimmelman for his @Nature paper today:
Hepatocytes promote liver metastasis of #PancreaticCancer by providing serine
nature.com/articles/s41586-0…
With @BarDafna @RichPossemato @KoelinaG @nyugrossman
